Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
2.580
-0.680 (-20.86%)
At close: Apr 1, 2025, 4:00 PM
2.700
+0.120 (4.65%)
After-hours: Apr 1, 2025, 7:11 PM EDT
Sagimet Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
14
Market Cap
83.06M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SGMT News
- 20 days ago - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 21 days ago - Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - GlobeNewsWire
- 25 days ago - Sagimet Biosciences' Denifanstat Should Be Worth More Today - Seeking Alpha
- 4 months ago - Sagimet: More Than Just A MASH Drug Development Biotech - Seeking Alpha
- 5 months ago - Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne - PRNewsWire
- 5 months ago - Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat - Seeking Alpha
- 6 months ago - Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology - GlobeNewsWire
- 6 months ago - Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH - GlobeNewsWire